These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 27792008)

  • 1. Of patents and patent disputes: The TNFα patent files. Part 1: Humira.
    Storz U
    Hum Antibodies; 2017; 25(1-2):1-16. PubMed ID: 27792008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Of patents and patent disputes - The TNFα patent files. Part 2: Enbrel, Remicade, Cimzia and Simponi.
    Storz U
    Hum Antibodies; 2018 Feb; 26(2):49-61. PubMed ID: 29439320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humira: the impending patent battles over adalimumab biosimilars.
    Norman P
    Pharm Pat Anal; 2016 May; 5(3):141-5. PubMed ID: 27087201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice.
    Scheinberg M; Castañeda-Hernández G
    Arthritis Res Ther; 2014 Dec; 16(6):501. PubMed ID: 25677586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of Biosimilars of Adalimumab.
    Kaushik VV
    J Assoc Physicians India; 2017 May; 65(5 Suppl):15-21. PubMed ID: 28836746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bringing Humira (Its Price) Down a Peg.
    Ladika S
    Manag Care; 2019 Jan; 28(1):7-8. PubMed ID: 30883314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
    Vermeire S; Louis E; Dewit O; Franchimont D; Moreels T; Ferrante M; Rahier JF; Van Hootegem P; De Vos M; Mana F; Baert F;
    Acta Gastroenterol Belg; 2015; 78(1):26-9. PubMed ID: 26118575
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost to Medicare of Delayed Adalimumab Biosimilar Availability.
    Lee CC; Najafzadeh M; Kesselheim AS; Sarpatwari A
    Clin Pharmacol Ther; 2021 Oct; 110(4):1050-1056. PubMed ID: 34145566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis.
    Lu X; Hu R; Peng L; Liu M; Sun Z
    Front Immunol; 2021; 12():638444. PubMed ID: 33889152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
    Yoo DH
    Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FKB327: An Adalimumab Biosimilar.
    Al-Salama ZT
    BioDrugs; 2019 Feb; 33(1):113-116. PubMed ID: 30712241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis.
    Zhao S; Chadwick L; Mysler E; Moots RJ
    Curr Rheumatol Rep; 2018 Aug; 20(10):57. PubMed ID: 30094742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
    Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TNFalpha therapy in psoriatic arthritis and psoriasis.
    Mease P
    Ann Rheum Dis; 2004 Jul; 63(7):755-8. PubMed ID: 15194567
    [No Abstract]   [Full Text] [Related]  

  • 16. Biosimilars in the United States: Emerging Issues in Litigation.
    Wong AY; Rumore MM; Chan AW
    BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis.
    Bellinvia S; Ashraf M; Polosa R; Edwards C
    Immunotherapy; 2017 Nov; 9(14):1133-1142. PubMed ID: 29067885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humira
    Norman P
    Pharm Pat Anal; 2017 May; 6(3):89-90. PubMed ID: 28485681
    [No Abstract]   [Full Text] [Related]  

  • 19. The economics of adalimumab for ulcerative colitis.
    Xie F
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):373-7. PubMed ID: 25817776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humira: the first $20 billion drug.
    Gibbons JB; Laber M; Bennett CL
    Am J Manag Care; 2023 Feb; 29(2):78-80. PubMed ID: 36811981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.